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Abstract
Background: Stat1 gene-targeted knockout mice (129S6/SvEvTac-Stat1tm1Rds) develop estrogen receptor-positive
(ER+), luminal-type mammary carcinomas at an advanced age. There is evidence for both host environment as well
as tumor cell-intrinsic mechanisms to initiate tumorigenesis in this model. In this report, we summarize details of
the systemic and mammary pathology at preneoplastic and tumor-bearing time points. In addition, we investigate
tumor progression in the 129:Stat1−/− host compared with wild-type 129/SvEv, and we describe the immune cell
reaction to the tumors.
Methods: Mice housed and treated according to National Institutes of Health guidelines and Institutional Animal
Care and Use Committee-approved methods were evaluated by histopathology, and their tissues were subjected to
immunohistochemistry with computer-assisted quantitative image analysis. Tumor cell culture and conditioned
media from cell culture were used to perform macrophage (RAW264.7) cell migration assays, including the 129:
Stat1−/−-derived SSM2 cells as well as control Met1 and NDL tumor cells and EpH4 normal cells.
Results: Tumorigenesis in 129:Stat1−/− originates from a population of FoxA1+ large oval pale cells that initially
appear and accumulate along the mammary ducts in segments or regions of the gland prior to giving rise to
mammary intraepithelial neoplasias. Progression to invasive carcinoma is accompanied by a marked local stromal
and immune cell response composed predominantly of T cells and macrophages. In conditioned media
experiments, cells derived from 129:Stat1−/− tumors secrete both chemoattractant and chemoinhibitory factors, with
greater attraction in the extracellular vesicular fraction and inhibition in the soluble fraction. The result appears to
be recruitment of the immune reaction to the periphery of the tumor, with exclusion of immune cell infiltration
into the tumor.
Conclusions: 129:Stat1−/− is a unique model for studying the critical origins and risk reduction strategies in age-
related ER+ breast cancer. In addition, it can be used in preclinical trials of hormonal and targeted therapies as well
as immunotherapies.
Keywords: Estrogen receptor, Luminal breast cancer, Stat1-knockout mouse, Pathobiology, Tumor
microenvironment, Tumor immunology
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Background
Mammary tumors in the 129/SvEv mouse strain with
knockout (KO) of Stat1 (129S6/SvEvTac-Stat1tm1Rds;
129:Stat1−/− or Stat1-null) are unique among genetically
modified mouse (GMM) models of human breast cancer
[1]. In contrast to most other mouse models of human
breast cancer, the resulting tumors are ovary-dependent
and have uniformly high levels of estrogen receptor
(ER)-α and progesterone receptor (PR), as well as ele-
vated transcription of Forkhead box A1 (FoxA1) [2].
FoxA1-positive cells in the mammary gland are known
to originate in the mammary ducts rather than in the
lobuloalveolar units [3] and thus could potentially give
rise to ductal tumors rather than alveolus-based tumors
that occur in most mouse models of mammary cancer
[4–6]. Further, Stat1-null females exhibit a prolonged
tumor latency that models the majority of human breast
cancers that are age-related [2, 7, 8]. Given these rele-
vant characteristics, we sought to investigate the origins,
evolution, and progression of tumors in the context of
the whole animal, with detailed observations afforded by
anatomic, histologic, endocrine function, immune cell
reaction, and molecular evaluations of organs from aged
129:Stat1−/− mice [9–12].
The 129:Stat1−/− model has been used to study a var-
iety of phenomena, including natural killer cell responses
during obligate intracellular pathogen infection, immune
editing, mammary gland development [2, 7, 13–15], and
mammary tumorigenesis [2]. Regarding changes in the
mammary glands, these studies documented deficiencies
in the immune and endocrine systems; dramatic changes
in cytokine concentrations both systemic and tissue; lo-
calized effects on mammary development and the micro-
environment; and the spontaneous, cell-autonomous
development of mammary neoplasia [2, 16]. Reciprocal
mammary gland transplantation in immune intact syn-
geneic 129/SvEv and in 129:Stat1−/− mice, as well as tis-
sue coculture experiments, has facilitated isolation and
investigation of the host environment [7].
The luminal mammary carcinomas in 129:Stat1−/−
occur as spontaneous neoplasms in nulliparous and
parous females, and they have a prolonged latency
[2]. The tumor cytology is unique among GMM
models of mammary cancer and is relatively uniform
throughout all tumors. Molecular analysis of Stat1-
null tumors revealed decreased levels of Janus kinase
2 (JAK2) and downstream activity resulting in tumori-
genesis [2, 16]. Moreover, genomic analysis of mam-
mary tumors arising in the 129:Stat1−/− mouse
established they almost always harbored a truncating
exon 10 mutation of the prolactin receptor (PRLR)
that was tumorigenic when heterozygously expressed
in embryonic fibroblasts lacking Stat1 but overex-
pressing Jak2 [17].
Although mammary gland development in the
129:Stat1−/− model was initially described as normal [2],
a subsequent and more detailed study revealed that the
mammary glands had delayed development, defective
branching morphogenesis, and abnormal terminal end
buds [7]. Further, the gland-free KO mammary fat pad
produces only low concentrations of a number of growth
factors/cytokines [7]. Interestingly, mammary growth
and the cytokine profile can be restored to normal levels
either with pregnancy or by administering exogenous
progesterone and prolactin (PRL) [7]. Therefore, the
129:Stat1−/− model provides an opportunity to investi-
gate the dependence of mammary development and
tumorigenesis on endocrine-cytokine interactions be-
tween the tumor and the microenvironment.
KO of Stat1 in other mouse strains and using other
targeting approaches does not lead to spontaneous pri-
mary mammary tumors. When these Stat1−/− mice are
crossed with Neu-expressing GMM, the resulting bigenic
animals do, however, exhibit accelerated tumorigenesis,
suggesting that STAT1 functions as a tumor suppressor
[18–21]. Forced breeding of Balb/c:Stat1−/− females
stimulated mammary neoplasia but resulted in a variety
of tumor types that are different from the homogeneous
129:Stat1−/− tumors [21]. Thus, the 129:Stat1−/− model
offers the unique opportunity to identify host and tumor
factors modeling similar human breast cancers [2, 17].
Mammary tumors in 129:Stat1−/− occur exclusively in
aged females and depend on hormonal and microenvi-
ronmental changes. Their ER+ luminal phenotype, which
is the most common phenotype in human breast cancers
and the most common phenotype associated with ad-
vanced age, occurs only in Stat1 KO on the 129 back-
ground, implying there are genetic modifiers of this
phenotype.
We have studied the origin and progression of primary
mammary tumors in 129:Stat1−/− in our colony from
early development [7] and, now, to over 2 years of age
(120 weeks). We report the findings of additional mor-
phological abnormalities in the Stat1−/− mouse that re-
flect systemic endocrine and environment effects, as well
as the identification of a FoxA1+ large oval pale (LOP)
cell that appears along some Stat1-null ducts as their
hosts approach tumor-bearing age. These LOP cells pre-
cede the invasive cancers, and their distribution is con-
sistent with evolution of a mutant mammary epithelial
cell (MEC) clone that populates contiguous segments of
the mammary gland.
A role for the microenvironment in the initiation of
cancers is clear, given the age dependency of the cancers
and their thoracic location. We also describe an un-
usually strong host immune response (compared with
other GMM mammary cancer models, including GMM
transplants such as the Met1 model Fig. 1a [22]) to the
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invasive Stat1-null neoplasm that increases with lesion
progression. These host responses are similar in both
129:wild-type (129:WT) and 129:Stat1−/− hosts, suggest-
ing that the tumor cells produce chemoeffectors, which
were subsequently found in both the soluble and the
exosome fractions from cultured tumor cells.
Methods
Mouse model
129:Stat1−/− mice [7, 23] were provided by the Schreiber
laboratory (Washington University, St. Louis, MO,
USA), and 129S6/SvEvTac mice were purchased from
Taconic Farms (Hudson, NY, USA). Mice were housed
in a vivarium according to National Institutes of Health
guidelines, and all animal experiments were performed
following procedures approved by the UC Davis Institu-
tional Animal Care and Use Committee. The procedures
for transplantation [7] and the conditions for maintain-
ing mice [24] were described previously.
Histopathology and whole-mount preparation
Most tissues were fixed in 10% neutral buffered formalin
(NBF) at room temperature for 24 h, then placed in 70%
ethanol until processing, which was normally within
24 h. To validate the immunohistochemical staining with
NBF-fixed samples, some tissues were fixed in zinc-
based fixative as described elsewhere [24]. Procedures
for infiltrating tissue with paraffin, sectioning, and
hematoxylin and eosin (H&E) staining were described
previously [24]. The preparation of whole mounts of
mouse mammary glands was carried out as previously
described [7].
Transplants
Fragments (1 mm3) of freshly dissected tumors were
transplanted into uncleared thoracic and inguinal mam-
mary fat pads of 3- to 6-week old nulliparous WT and
Stat1-null females under appropriate anesthesia and
sterile conditions as previously described [7]. The
Fig. 1 Kaplan-Meier and T50 plots comparing tumorigenesis in 129:Stat1
−/− and other published models. a Kaplan-Meier plots showing survival
curves for parous and nulliparous 129:Stat1−/− as compared with those from the Wnt, Neu, PyVMT, Tp53−/−, and Cdh1−/−/Tp53−/− models. The blue
highlighting indicates the ages in weeks when mice are considered mature, middle-aged, and old adults as calculated by Harrison’s laboratory
[44]. b Chart of the T50 values for 129:Stat1
−/− and a variety of common mouse models of human breast cancer. Where the T50 was not provided,
the median value was used as the T50. The blue highlighting indicates the ages in weeks during which mice are considered mature, middle-aged,
and old adults [44]
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animals were monitored at least twice per week. Growth
of palpable tumors was noted and measured in two di-
mensions using calipers. The volumes were calculated
using the average diameter [4/3 × π × (d1 + d1/4)3].
Immunohistochemistry
Immunohistochemistry (IHC) was performed as previ-
ously described [7, 24]. Stained slides were scanned on
an Aperio AT2 ScanScope (Leica Biosystems, Buffalo
Grove, IL, USA), and digital images were viewed using
the ImageScope application (Leica Biosystems). Digital im-
ages were captured and processed using Photoshop soft-
ware (Adobe Systems, San Jose, CA, USA). The imaging
analysis for counting marker-positive cells was performed
with inForm Cell Analysis software (PerkinElmer,
Waltham, MA, USA). Multiplex IHC was performed with
tyramide signal amplification (TSA)-based fluorescence
color visualization [25]. TSA-based multiplex IHC was
performed according to the manufacturer’s protocol
(PerkinElmer). FoxA1, epithelial cell adhesion molecule
(EpCAM), and keratin-14 (KRT14) were detected with
TSA Plus fluorescein, cyanine 3 (Cy3), and Cy5, respect-
ively. Visualization of multiplexed images was performed
with an LSM710 laser scanning confocal microscope (Carl
Zeiss Microscopy, Oberkochen, Germany). Antibodies
used were anti-ER-α (clone MC-20; Santa Cruz Biotech-
nology, Dallas, TX, USA), anti-PR (polyclonal; Dako North
America, Carpinteria, CA, USA), anti-Ki67 (clone Ab-4,
Lab Vision; Thermo Fisher Scientific, Fremont, CA, USA),
anti-CD3 (clone SP7; Abcam, Cambridge, MA, USA),
anti-CD4 (clone RM4-5; eBioscience, San Diego, CA,
USA), anti-CD8a (clone 4SM15; eBioscience), anti-F4/80
(clone MCA497, AbD Serotec; Bio-Rad Laboratories,
Hercules, CA, USA), anti-B220 (clone RA3-6B2; BD
Biosciences, San Jose, CA, USA), anti-KRT14 (Covance
Poly19053; BioLegend, San Diego, CA, USA), anti-
FoxA1 (clone EPR10881; Abcam), anti-EpCAM (EPR677;
Abcam), anti-KRT8/18 (CK209; Fitzgerald Industries
International, Acton, MA, USA), and anti-type IV collagen
(polyclonal; Abcam).
Collecting conditioned media
A Stat1-null cell line (SSM2) [2], an MMTV-NDL-de-
rived cell line (NDL) [26], and an MMTV-PyMT-derived
cell line (Met1) [22] were cultured in T75 culture flasks
at 1 × 106 cells in growth medium (DMEM supple-
mented with 10% FBS) for 2 days. A phenotypically nor-
mal MEC line, EpH4, was cultured as described
previously [27]. To prepare conditioned medium (CM)
from each cell line, cells were rinsed three times with
serum-free medium and then cultured in 10 ml of serum-
free medium for 48 h. CM was collected, centrifuged to
eliminate cells and debris, and filtered (0.2 μm). To isolate
extracellular vesicles (EVs), CM was ultracentrifuged at
100,000 × g for 2 h. The pellet (EV-rich fraction) was
resuspended in DMEM with the same volume as the
supernatant (soluble fraction).
Time-lapse migration assay
The green fluorescent protein (GFP)-tagged H2B [28]
was transduced into RAW264.7 mouse macrophages
(American Type Culture Collection, Manassas, VA,
USA) using pLenti-EF1a-Puro bearing a GFP-tagged
H2B complementary DNA [27]. Preparation of lentiviral
particles and transduction of target cells were performed
as previously described [27]. To maintain GFP-H2B-
positive cells, growth medium was supplemented with
0.5 μg/ml puromycin. To observe RAW264.7/GFP-H2B
cell migration, cells were plated at 2 × 104 cells/well of
an eight-well Lab-Tek II chambered coverglass (Thermo
Fisher Scientific, Waltham, MA, USA) in growth
medium for 2 days before stimulating cell migration
with CM. Fluorescence was visualized with an LSM710
confocal microscope equipped with a temperature- and
CO2-controlled chamber [29, 30]. Before cell migration
was analyzed, cells were rinsed twice and maintained in
400 μl of serum-free DMEM for 2 h. The action of
RAW264.7/GFP-H2B cells was monitored at 5-minute
intervals for more than 8 h. Cell migration was evaluated
using time-lapse images with Imaris software (Bitplane,
South Windsor, CT, USA).
Transwell migration assay
RAW264.7 cells were resuspended in DMEM at a dens-
ity of 1 × 106 cells/ml, and 100 μl of resuspended cells
were placed into the upper chamber of Transwell culture
inserts (8-μm pore size) in 24-well plates (Corning,
Corning, NY, USA). Quantities of 600 μl of DMEM or
CM from each cell line were applied in the bottom
chamber for 5 h to test the chemoattractant activity.
Cells on the underside of the insert were fixed with 70%
ethanol for 10 minutes and then stained with 0.2% crys-
tal violet before rinsing to remove background staining
and air-drying, followed by microscopic imaging.
Statistical analysis
All statistical analyses were done using Prism 7 software
(GraphPad Software, La Jolla, CA, USA). Kaplan-Meier
plots were generated to compare the tumorigenesis of
nulliparous and multiparous 129:Stat1−/− animals (Fig. 1).
The difference was detected with the log-rank test. Simi-
larly, Kaplan-Meier plots were created to compare the
latency of palpable tumor onset between tumors trans-
planted to 129:Stat1−/− or 129:WT hosts. The difference
was detected with the log-rank test. The asymmetries of
primary tumor occurrence between left-right and
caudal-cephalad mammary fat pads (Additional file 1:
Table S1) were tested with a binomial test.
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Results
Tumor incidence and distribution
A total of 24 palpable mammary tumors developed in 20
female 129:Stat1−/− mice. Tumors were detected in two
tumor-bearing parous females before 1 year of age (at 32
and 47 weeks). The other 18 tumor-bearing mice devel-
oped tumors between the ages of 1 year (52 weeks) and
2.3 years (120 weeks). For comparison, 30 female
129:Stat1−/− mice without palpable tumors were killed at
various times beyond 52 weeks of age (Additional file 1:
Table S2). The differences in time to tumor onset be-
tween parous and nulliparous females in our colony
were significant (p = 0.038 by log-rank test), consistent
with the initial report about the Washington University
in St. Louis colony [2] that had an equally prolonged
latency and incomplete (~53%) penetrance. Although
the tumor incidence in our cohort remained consistent
after 1 year of age (35%), subsequent pathological ana-
lysis revealed that surviving nulliparous females had
mammary intraepithelial neoplasia (MIN) lesions, sug-
gesting that the penetrance of mammary tumors could
approach 100% were animals to age even further.
The 13 tumor-bearing nulliparous females ranged in
age at tumor onset from 73 to 120 weeks, with 50%
incidence at 91 weeks. The comparable 24 tumor-free
nulliparous WT females covered a similar age range
(53–120 weeks) and a similar average age when killed
(83 weeks). Similar to a previous report [2], pregnancy
shortened tumor latency from T50 = 91 weeks to T50 =
78 weeks. A comparable cohort of six tumor-free parous
KO mice was examined (mean age 83 weeks, range 52–
95 weeks). The fact that not all aged 129:Stat1−/− ani-
mals were tumor-bearing within 120 weeks also suggests
a stochastic component to tumor initiation in addition
to the GMM intrinsic susceptibility (Fig. 1).
When these data are compared with the recorded or
calculated T50 from other GMM models that are KOs of
tumor suppressor genes or employ a mammary-specific
promoter driving the targeted expression of an onco-
gene, the 129:Stat1−/− model stands out as being unique
(Fig. 1). The T50 for 129:Stat1
−/− is over three times the
mean T50 (28 weeks) of these other GMMs and 40 weeks
longer than the closest model, MMTV-cMyc [31]. When
compared with other GMMs using their respective
Kaplan-Meier plots, the 129:Stat1−/− model plot does
not overlap with any of those for commonly reported
models (Fig. 1).
Tumor topography
The palpable mammary tumors showed a notable cephalad
(thoracic) to caudal (inguinal) dominance (Additional file 1:
Table S1). Eighty-seven percent (21 of 24) of tumors were
detected in the thoracic mammary fat pads (p = 0.0003 by
binomial test) (Additional file 1: Table S1). These
distributions are consistent with the topographical asym-
metries previously described in other models and suggest
that the local microenvironment influences tumor develop-
ment [32]. In addition, the majority of palpable tumors
were proximate to the nipple rather than at the periphery
of the fat pad. These masses around or adjacent to the
nipple can also explain the dilation and congestion of some
more distal ducts (Additional file 2: Figure S1).
Necropsy pathology
Necropsy of the three subcohorts (129:WT, tumor-free
129:Stat1−/−, and tumor-bearing 129:Stat1−/−) was per-
formed with attention to microscopic mammary and non-
mammary pathologies that may correlate with the tumor-
bearing phenotype (Figs. 2 and 3). The older animals in all
three cohorts shared sporadic conditions associated with
aging, such as bronchioloalveolar adenoma, eosinophilic
(crystalline) pneumonitis, atrophic cystic hyperplasia of
the endometrium, segmental interstitial nephritis, ovaries
with luteinized stroma and fewer Graafian follicles, and
low-grade small cell lymphoma [33]. The adrenal glands,
thyroid glands, pancreas, and pituitary glands were all
disease-free. Significantly, the vaginal mucosa in all three
cohorts had evidence of ovarian function at older ages.
For example, at 96 weeks of age, the vaginal mucosa of
both KO and WT displayed cornification (estrus), inflam-
mation (metestrus), or mucinous differentiation (proes-
trus). The vaginal mucosa is a standard histological
indication of stage of the estrous cycle (see Fig. 3). In con-
trast, the mammary glands and ovaries had features
unique to each cohort, as described below (Figs. 2 and 3).
129:WT
Two 129:WT females were held until 97 weeks. One fe-
male was parous and had eosinophilic pneumonitis, a
polycystic nonproliferative endometrium, and luteinized
ovarian stroma with scattered follicles. One ovarian
bursa was cystically dilated. The mammary glands had
mild lobuloalveolar development with scattered inflam-
matory (squamous) nodules, consistent with persistent
postinvolutional hyperplasia [34]. The mammary glands
of the nulliparous 97-week-old female were devoid of in-
flammatory nodules and hyperplasia. The uterus and
ovaries of the two mice were similar in that they had a
cystic endometrium and luteinized ovarian stroma with
reduced follicles.
129:Stat1−/−
The 129:Stat1−/− mice younger than 32 weeks old (n = 42)
did not have detectable histopathology in any of their or-
gans. The mammary glands of non-tumor-bearing
129:Stat1−/− females that were aged 52 weeks or older
(n = 32) were also examined. Of the older nulliparous
females without tumors, three had microscopic MIN
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in their mammary glands (Fig. 2). In contrast, the
mammary glands of fifteen of the twenty-three
129:Stat1−/− females bearing preneoplastic MIN or tu-
mors had various hyperplastic and dysplastic features
(Fig. 2e, f ).
Mammary glands in 12 of the 20 tumor-bearing
animals also had lobuloalveolar hyperplasia that
sometimes obscured the MIN at the gross examination
level. The remaining eight females had sparsely branched
mammary ductal networks. The lobuloalveolar hyperplasia
B C
D
b
a
c
d
Fig. 3 Observations in knockout gynecology. This figure illustrates the ovaries, uterus, and vagina of a 120-week-old 129:Stat1−/−nulliparous
female. a This low-magnification image shows that the right ovary is obliterated by a large cyst (green asterisk). Arrows B, C, and D indicate regions
of interest for the higher-magnification images shown in b, c, and d, respectively. Scale bar = 5 mm. b The contralateral ovary is largely replaced
by multiple vascular channels filled with red blood cells. Scale bar = 400 μm. c The cyst is lined with a tall columnar epithelium with apical nuclei
characteristic of rete cysts of the mouse ovaries. Scale bar = 200 μm. d In spite of the destruction of the ovaries, the vaginal surface has a layer
of bluish mucinous cells associated with proestrus. This indicates a functional estrous cycle. Scale bar = 100 μm
a
b
c
d
e
f
Fig. 2 Normal and diseased 129:Stat1−/− mammary glands with mammary intraepithelial neoplasia (MIN). This figure compares representative
mammary whole mounts and representative hematoxylin and eosin (H&E)-stained histology for (a and b) an 88-week-old nulliparous 129:wild
type (129:WT), (c and d) tumor-free 129:Stat1−/−, and (e and f) 120-week-old nulliparous tumor-bearing 129:Stat1−/−. The tumor-free knockout and
WT are normal (a–d). The whole mount from the nulliparous, tumor-bearing, 120-week-old 129:Stat1−/− female shows extensive lobuloalveolar
development and two cystic MIN (arrows) (e). The H&E staining shows cystic lesions and a dense duct without a visible lumen filled with
precancerous large oval pale cells (MIN) (f). Scale bars = 500 μm
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in 9 of 13 nulliparous tumor-bearing females is note-
worthy because these animals had not been pregnant or
exposed to the associated hormonal environment. In
addition, most of these animals had dilated mammary
ducts filled with proteinaceous “milky” white fluid
(Additional file 2: Figure S1). The heterogeneity of
mammary development was striking where different
levels and patterns of lobuloalveolar development
were present in the same mammary gland (Fig. 2e).
The other four nulliparous tumor-bearing females had
underdeveloped and stunted mammary ductal networks
that failed to fill the fat pad [7].
Ovaries
All 129:Stat1−/− females older than 1 year of age had
periovarian or ovarian tubules identified as mesonephric
or rete tubules [35, 36] (Fig. 3a). In addition, thirty-one
of the fifty 129:Stat1−/− females had ovaries with mul-
tiple cysts, some of which completely ablated the ovaries
(Fig. 3b). Most cysts were lined by a simple attenuated
epithelium. However, many ovarian cysts were lined by a
tall columnar epithelium with apical nuclei signifying
them as rete cysts (Fig. 3c) [36]. Notably, in this specific
case, the contralateral ovary was obliterated by a highly
vascular hemorrhagic mass (Fig. 3d). However, the va-
gina had a mucinous epithelium indicative of proestrus
and continued estrous cyclicity (Fig. 3d). One 84-week-
old tumor-bearing female had histologically normal
ovaries with multiple Graafian follicles. Ovaries without
cysts showed luteinized stroma and reduced germinal
follicles. Therefore, tumorigenesis did occur in the
absence of ovarian cysts, and not all mice/females with
ovarian cysts developed mammary tumors.
Uterus
The uterus of 129:Stat1−/− mice tended to be hypervas-
cular, where five females had dense tangles of vessels
that were classified as hemangiomas. These uteri had
frequent dilated vessels with blood and fibrin thrombi.
One tumor-bearing animal had a stromal sarcoma of the
uterus, and another had an endometrial focus consistent
with adenocarcinoma.
Origin and evolution of Stat1-null tumors
The early, preinvasive MIN lesions in 129:Stat1−/− fe-
males have been mentioned previously without morpho-
logic descriptions [2, 17]. These lesions are atypical foci
that stand out from the surrounding normal mammary
epithelium but remain confined within the basement
membrane (Figs. 2 and 4), thus fitting the morphological
criteria for MIN [4, 37]. These MIN could be found
contiguous or adjacent to invasive tumors as well as in
nontumorous glands and ducts of 129:Stat1−/− tumor-
bearing females, as well as in some tumor-free females
older than 52 weeks. These MIN never occurred in
129:WT females, including two 97-week-old females, or
in disease-free 129:Stat1−/− females younger than 1 year
of age (n = 42).
The Stat1-null MIN are small, nonpalpable, and not
easily identified by gross inspection. Obvious lesions
can be identified at the subgross level in mammary
gland whole mounts as discrete, hypercellular foci
that stand out from the background, typically as solid
ducts, micronodular clusters, or small cysts (Fig. 4,
Additional file 2: Figure S2e–g). The smaller MIN
were not associated with a significant host response.
The larger, presumably more advanced lesions were
surrounded by a significant host inflammatory re-
sponse that had a rich mast cell component but were
composed primarily of T cells, macrophages, and in-
creased vascularity (Fig. 4d, Additional file 2: Figure S2h).
The distribution of MIN in affected glands was
restricted to one or several ducts of the mammary
network, whereas adjacent ducts had normal histology
and cytology (Fig. 5a, b).
Microscopically, the MIN were characterized by clus-
ters of unique atypical cells that stood out from the adja-
cent MEC. These dysplastic cells had large, oval,
moderately pleomorphic nuclei with an open chromatin
pattern and prominent nucleoli with abundant pale cyto-
plasm (LOP cells) (Fig. 6a, Additional file 2: Figure S3).
These LOP cells are large relative to adjacent luminal
and basal MECs (Fig. 6, Additional file 2: Figure S3). In
addition, LOP cells in MIN and associated malignancies
were KRT8/18+, with some also being KRT14+ but
negative for smooth muscle actin (Additional file 2:
Figure S4). The LOP cells were further characterized
using multiplexed immunofluorescence, which re-
vealed nuclear staining for FoxA1 in neoplastic
EpCAM+ luminal cells and in sparse populations of
KRT14+ basal-like cells, suggesting that FoxA1+ cells
within MIN might be pluripotent (Fig. 6g, g′). The
cells in Stat1-null invasive carcinomas (tumors)
shared these immunophenotypic characteristics.
Neoplasms in Stat1-null mice contained LOP cells within
MIN (Figure 6b, c; Additional file 2: Figure S5). These LOP
cells were also interspersed among normal ductal MECs
along relatively normal ducts (Fig. 6a, b, and d–f;
Additional file 2: Figure S5). In general, the LOP cells
appear to be more basally oriented but remained
inside the myoepithelial layer (suprabasal). In some
presumably more advanced cases, small collections of
LOP cells appeared as multicellular nodules along the
ducts (Figs. 5 and 6). In other instances, these LOP
cell nodules formed outgrowths attached to but bul-
ging out from the main duct (Fig. 5, Additional file 2:
Figure S1). These nodules resembled abortive ductal
side buds in normal mammary glands.
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a b
Fig. 5 The diseased duct. A low-magnification view of the mammary gland from the tumor-free right inguinal (#4) mammary fat pad of a
nulliparous 106-week-old tumor-bearing 129:Stat1−/− female showing four engorged ducts (asterisks) coursing through the mammary fat pad (a).
LN Lymph node. Scale bar = 2 mm. Note that the large oval pale (LOP) cell-forming multiple aberrant side buds are restricted to one duct
(green box) (b) and have a nodular profile (arrows). Other main stem ducts and their branches have smooth outlines and a normal basal and
luminal bilayered epithelium (arrowheads). In addition, Additional file 2: Figure S3 shows quantitation of the distribution of LOP cells. The DNA
sequences of laser capture microdissection from the diseased duct within the green box showed three different single-nucleotide variations in the
prolactin receptor (PRLR) gene. A higher-magnification image shows the solid abortive side buds filled with LOP cells of the diseased duct. Scale
bar = 400 μm. Figure 6c shows a higher-magnification view of progesterone receptor-stained LOP cells in the solid nodules of the same duct
a
c
b
d
Fig. 4 Histological types of mammary intraepithelial neoplasia (MIN). a–d This figure illustrates the three types of MIN lesions found in a 129:Stat1−/−
female, stained for Forkhead box A1 (a–c; 106-week-old nulliparous female) and CD3 (d; 90-week-old tumor-bearing female). a Ductal pattern with a
branching duct filled with large oval pale (LOP) cells. Scale bar = 300 μm. b Cystic with expanded luminal cystic space lined by LOP cells. Note the lack
of any appreciable host response in a and b. Scale bar = 300 μm. c Solid micronodular pattern with small nests of cells in dense connective tissue.
Scale bar = 200 μm. d A higher-magnification image of a more advanced solid nodular MIN showing dilated vessels and dense round cell infiltrate with
CD3+ T cells (see Fig. 9). Scale bar = 100 μm
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The distribution of LOP cells and MIN was restricted
to one or several ducts of the mammary network in af-
fected glands (Fig. 5), whereas the other adjacent ducts
had an entirely normal histology and associated cytology
(Fig. 5). The LOP cells in the “diseased” duct were
FoxA1+, ER+, and PR+ (Fig. 6, Additional file 2: Figure
S6). Further, laser capture-microdissected samples from
the diseased duct illustrated in Fig. 5 were extracted, and
exon 10 of the PRLR was sequenced. The specific duct
(right inguinal mammary gland) contained three separ-
ate nontruncating single-nucleotide variants. In contrast,
the adjacent ducts and lymph node had a normal WT
PRLR sequence, whereas the palpable mammary tumor
in the same animal’s left thoracic mammary gland was
heterozygous for a truncating PRLR mutation similar to
those previously described [17].
Tumor microscopic description
The microscopic characteristics of the 129:Stat1−/− tu-
mors have been described previously and display consist-
ently similar morphologic phenotypes from tumors in
one mouse to tumors in the next (low intertumoral het-
erogeneity) [2]. In contrast, spontaneous tumors from
Trp53- and Brca1-KO mice, as well as from pregnancy-
induced Balb/c:Stat1−/− tumors, have a mixture of tumor
types, with basal-like and “Wnt pathway” phenotypes be-
ing predominant [5, 21, 38]. Balb/c:Stat1−/− mice crossed
with mice expressing other oncogenes develop tumors
a b c
d e
g g’
f
Fig. 6 Large oval pale (LOP) cells in 129:Stat1−/− mammary glands developing cancer. The figure illustrates the potential cancer-initiating LOP cells in
129:Stat1−/− mammary intraepithelial neoplasia (MIN) and tumors. The LOP cell has a pale cytoplasm and a large oval nucleus with clear chromatin.
These cells initially appear in ducts before MIN are detectable. a Hematoxylin and eosin (H&E) staining of duct shows LOP cells standing out from the
normal luminal layer (arrows). The normal mammary epithelial cells (MECs) have densely staining nuclei and relatively sparse cytoplasm. These LOP cells
were found only in aging 129:Stat1−/− females with tumors or MIN. Scale bar = 100 μm. b H&E-stained image shows LOP cells filling a duct (asterisk)
and populating side buds (arrows). Scale bar = 100 μm. c Progesterone receptor (PR)-stained tissue shows side budding that is forming an early MIN
lesion. Scale bar = 70 μm. d Forkhead box A1 (FoxA1)-positive LOP cells were observed in a duct from a tumor-bearing mouse. An adjacent duct was
negative for FoxA1. Scale bar = 70 μm. e and f Immunohistochemical (IHC) stains show uniformly positive LOP cells for (e) estrogen receptor (ER) and
(f) PR. FoxA1+/ER+/PR+ LOP cells in tumor are shown in Additional file 2: Figure S6. g and g′ A multiplex IHC image shows FoxA1 (white), epithelial cell
adhesion molecule (red), and keratin 14 (green) expression in MIN in 129:Stat1−/−. g′ Higher-magnification image of inset shown in g. Note the dual
staining for basal (green) and luminal (red) antigens in many of the LOP cells, indicating that they are dual-staining and potentially pluripotential
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with phenotypes identical to those of the oncogenic
transgene [18–20]. The signature 129:Stat1−/− tumor
phenotype consists of nodular nests of cells with large
oval nuclei and abundant pale cytoplasm. These cells are
cytologically identical to the LOP cells found in MIN.
Eighty percent to 95% of these cells in MIN and tumors
were immunopositive for ER, PR, and FoxA1 (Fig. 4,
Additional file 2: Figures S5 and S6).
Invasion and metastasis
In contrast to the expansile margins found in most mouse
mammary tumors [5], Stat1-null tumors are characterized
by local invasion into the surrounding tissues (Additional
file 2: Figure S7a). Metastasis to local mammary lymph
nodes was observed in three tumor-bearing KO mice
(Additional file 2: Figure S7b). Occasional vascular invasion
was also observed (Additional file 2: Figure S7c and d).
However, only one tumor-bearing animal had micrometas-
tases to the lung, which is the most common site of metas-
tasis in GMM models [5]. There was no evidence of
metastasis to other organs.
Test by transplantation
A more detailed study of the 129:Stat1−/− neoplastic growth
was performed by transplanting both primary MIN and
tumor tissues. Multiple attempts to isolate and transplant
MIN-type lesions in syngeneic WT mice failed to produce
an outgrowth line. However, primary tumors were readily
transplanted into the intact mammary glands of young WT
female mice and into young, age-matched 129:Stat1−/− fe-
male mice (Fig. 7). Interestingly, transplants into young
WT hosts became palpable and attained volume endpoints
sooner than the same tumor transplanted into young
129:Stat1−/− hosts (p = 0.021 by log-rank test). Once tumors
were palpable, their growth rates were similar (Additional
file 2: Figure S8). Thus, when the experiments were termi-
nated at 53 days, the tumor volumes in the WT hosts were
10 to 100 times greater than those in the KO hosts (p =
0.0295 by t test). This finding is comparable to that for
transplanting normal mammary epithelium reported previ-
ously [7], which suggested that the mammary stroma of
young (6–12 weeks old) 129:Stat1−/− mice is less supportive
of tumor growth than stroma in age-matched WT hosts.
a a’ b
c d
e f
g h
b’
Fig. 7 Immune cells in 129:Stat1−/− tumor transplants in fat pads of 129:wild-type (129:WT) and 129:Stat1−/− mice. Hematoxylin and eosin-stained
tissue sections of tumor transplants grown in inguinal fat pads of (a, a′) 129:WT and (b, b′) 129:Stat1−/− mouse mammary fat pads. a′ and b′
Higher-magnification images of tumor-stroma boundaries in a and b. Also shown are (c, d) macrophages, (e, f) T lymphocytes, and (g, h) B
lymphocytes detected in 129:Stat1−/− tumor transplants in (c, e, g) 129:WT and (d, f, h) 129:Stat1−/− mice. KO Knockout
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Host response
The Stat1−/− tumors exhibited a pronounced local in-
flammatory response at the interface of tumor cells and
surrounding stroma. In contrast to mammary tumors
from other GMM models [5], each 129:Stat1−/− tumor
was surrounded by a thick mantle of host inflammatory
cells and fibrosis (Fig. 7, Additional file 2: Figure S9).
The inflammation consisted primarily of a nearly equal
mixture of F4/80+ macrophages and CD3+ T lympho-
cytes in tumor-adjacent stroma. Quantitation of IHC
marker-positive cell density in tumor and tumor-
associating stroma in spontaneous Stat1-null tumors
(Additional file 2: Figure S9) indicated tumor-infiltrated
F4/80+ cells were at a significantly (p < 0.0001) lower
density (6 cells/mm2, SE = 2) than the cellular density in
the stroma (2580 cells/mm2, SE = 473). CD3+ cells were
also significantly (p < 0.0001) less densely populated in
tumors (262 cells/mm2, SE = 59) compared with the
stroma (3590 cells/mm2, SE = 439). Thus, significantly
fewer immune cells penetrated the tumor, with more
intratumoral infiltration of T lymphocytes than mac-
rophages. In addition, the density of B-cell lympho-
cytes was significantly (p < 0.0001) lower in tumors
(34 cells/mm2, SE = 6) than in the stroma (381 cells/
mm2, SE = 64), and the total number of B cells was
significantly lower than both macrophages (p = 0.0002)
and T lymphocytes (p = 0.0001).
The microenvironmental effect was further character-
ized in the grafts where primary tumor tissue was trans-
planted into mammary glands in WT host or KO host
animals. The IHC results showed a predominance of F4/
80+ macrophages and CD3+ T-lymphocytes in the
tumor-associated stroma (Fig. 7c–f ). The mean density
of F4/80+ cells in the tumor interstices from a WT host
was 19 cells/mm2 (SE = 3). By comparison, there was a
significantly higher density of F4/80+ cells in the sur-
rounding WT stroma (2472 cells/mm2, SE = 243). Simi-
larly, transplants of the same primary tumor into the age-
matched KO host also showed a predominance of macro-
phages in the stroma, with only 5 cells/mm2 (SE = 2) in
the tumor interstices and 2102 cells/mm2 (SE = 233) in
the stroma. The density of tumor-infiltrated macrophages
was significantly higher in the tumors engrafted into a
WT host than either the KO host or the spontaneous
Stat1-null tumors (Additional file 2: Figure S9b). Similarly,
CD3+ T lymphocytes were found in greater density in the
stroma of WT hosts (1990 cells/mm2, SE = 218) than in
the tumors (463 cells/mm2, SE = 54) (p < 0.0001). CD3+
cell density in KO hosts was significantly lower in both
tumors (353 cells/mm2, SE = 65) and stroma (1530
cells/mm2, SE = 194) than in the WT hosts, but the
CD3+ cell density was still higher in stroma than in tu-
mors (Additional file 2: Figure S9d). The ratios of
tumor-infiltrated immune cells to total cell count in
WT, KO host, and spontaneous Stat1-null tumors were
8%, 4.5%, and 2.2%, respectively, for CD3+ T lympho-
cytes and 0.77%, 0.24%, and 0.23% for F4/80 macro-
phages, respectively. In contrast, the cell density of B
lymphocytes in stroma was lower in transplants than
spontaneous 129:Stat1−/− tumors. The density of B
lymphocytes was higher in the stroma of WT hosts
than the tumors, but there was no significant difference
between the tumor and stroma in KO hosts (Additional
file 2: Figure S9f ). Thus, as with the primary tumors,
the host immune cells, especially macrophages, rarely
invaded the interstices of solid tumors. This pattern of im-
mune cell reaction to tumors has been described as the
“excluded infiltrate” phenotype, in contrast to tumors with
a sparse or absent immune reaction, as well as those with
an intratumoral “inflamed” phenotype [39].
Macrophage migration assays
Given the abundance of macrophages in the tumor-
associated stroma (Fig. 7, Additional file 2: Figure S9),
we reasoned that Stat1-null tumors might secrete
macrophage chemoattractants. To test this possibility,
migration assays with the RAW264.7 macrophage cell
line were performed using CM from (1) the Stat1−/−
tumor cell line SSM2, (2) the Stat1+/+ normal MECs
(EpH4, EpH3) and the polyoma middle T-induced mam-
mary tumor cell line Met1, and (4) the Neu-induced
mammary tumor cell line NDL. Migration of GFP-H2B-
transduced macrophages on 2D plastic was monitored
using time-lapse imaging to record track length and time
of the mobile cell nuclei.
Macrophages exposed to CM from the Stat1-null
tumor cell line SSM2, compared with CM from the
other three cell lines, had shorter track lengths for each
time-lapse interval and moved more slowly (Fig. 8a–f ).
Transwell migration assays also confirmed there was less
migration by RAW264.7 cells exposed to SSM2-CM
than by the other three cell lines (Fig. 8g). These ex-
periments suggest that Stat1-null cells either secrete
less chemoattractant or secrete factors that inhibit
macrophage migration.
To distinguish between these and other possibilities,
SSM2-CM was mixed with the markedly stronger che-
moattractive Met1-CM, and we compared this mixture
with DMEM/Met1 using the cell-tracking technique
(Fig. 8h). Whereas the mixture of Met1-CM and DMEM
(50%/50%) resulted in significant movement of RAW264.7
cells, the mixture of Met1-CM and SSM2-CM (50%/50%)
reduced the track length of Met1-CM to the level of
DMEM alone (Fig. 8g). This supports the notion that
SSM2-CM inhibits macrophage migration. This finding is
also consistent with the observation of macrophage exclu-
sion from the Stat1-KO tumors.
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The above results did not, however, explain the dense
accumulation of macrophages observed in the stroma
surrounding tumors (Fig. 7, Additional file 2: Figure S9),
raising the possibility that 129:Stat1−/− cells might se-
crete factors that can both stimulate and inhibit macro-
phage migration. Recent studies have shown that EVs/
exosomes can stimulate macrophage migration [40],
which could explain the attraction of macrophages to
the tumor-associated stroma. To test this possibility,
Met1-CM and SSM2-CM were fractionated into EV-rich
and soluble factor-rich portions using ultracentrifuga-
tion. The effects of these fractions on RAW264.7 cell
migration were subsequently tested using the Transwell
migration assay. Both the supernatant (soluble portion)
a
c
b
d
e
g h i
f
Fig. 8 Stat1-null cell line secretes macrophage migration stimulatory and inhibitory factors. Green fluorescent protein (GFP)-H2B-transduced
RAW264.7 macrophage cells (RAW264.7/GFP-H2B) treated with CM of (a) EpH4, (b) SSM2, (c) Met1, or (d) NDL cells were analyzed using time-
lapse imaging. a–d Images are GFP-H2B (green) in RAW264.7 cells and tracks of cells migrating. Color legend (bottom right corners of a–d) indi-
cates the time course and reflects the position at a certain time point. Cell migration was evaluated on (e) track length and (f) migration speed at
each time-lapse interval. g Graph shows the result of the Transwell migration assay with negative control (N_Ctrl; DMEM) and CM isolated from
EpH4, SSM2, Met1, and NDL cells. h SSM2-CM showed inhibitory activity on macrophage migration activated by Met1-CM. The effect of condi-
tioned medium of DMEM, Met1/DMEM (50%/50%), and Met1/SSM2 (50%/50%) on RAW264.7/GFP-H2B migration measured by time-lapse imaging
is shown. i RAW264.7 migration activity in response to either control (Ctrl; DMEM), the extracellular vesicle (EV)-rich fraction, or the soluble fraction
(Sol) of Met1- and SSM2-CM measured using the Transwell migration assay. The result indicates that the EV-rich fraction has a stimulatory activity
on macrophage migration. Data are mean ± SE. ****p < 0.0001, ***p < 0.001, *p < 0.05. ns Not significant (t test)
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and EV-rich fraction of Met1-CM induced higher levels
of macrophage migration than the same fractions from
SSM2-CM (Fig. 8i). Interestingly, the SSM2 EV-rich
fraction induced more macrophages to migrate than the
soluble fraction of SSM2-CM in the Transwell migra-
tion assay (Fig. 8i). The migration is notably compar-
able to that of the undiluted, noncentrifuged SSM2
media (Fig. 8g). This suggests that factors secreted as
EVs from Stat1-null tumors are more attractive to
macrophages than factors in the soluble portion that
inhibit macrophage migration. These could prevent
macrophages from infiltrating the tumor, helping to
create the excluded infiltrate phenotype.
Discussion
In the 129:Stat1−/− model of breast cancer, germline dele-
tion results in host, stromal, and epithelial changes that
de-suppress mammary adenocarcinoma [2]. These tumors
differ from those arising in mice harboring other Stat1-
targeting KO constructs or in other mice that are knocked
out for tumor suppressor genes such as Trp53 or Brca1.
129:Stat1−/− tumors share a signature histological and
cytological phenotype, with ER+, PR+, and FoxA1+ LOP
cells. This degree of tumor homogeneity suggests that the
same oncogenic driver leads to tumorigenesis [38]. In our
experience, the other tumor suppressor KO models
develop a variety of tumor types, suggesting they involve a
diversity of oncogenic drivers [5].
Consideration of oncogenesis in this Stat1−/− model
requires integrating the disease state within the context
of animal aging. We report that mammary tumorigenesis
in 129:Stat1−/− mice is associated with important patho-
logical features that make this model comparable to hu-
man luminal breast cancers. These include ductal origin,
topographical asymmetry, age-related ablation of the
ovaries, endocrine regulation, host immune response,
and tumor-secreted factors. Taken together, this model
uniquely reflects host-tumor relationships in an aging
host during mammary tumorigenesis.
Epithelial fitness: aging and pregnancy
The majority of human breast cancers occur in older
postmenopausal women. Ironically, this is the first
mouse model that directly relates age to mammary
tumorigenesis. The prolonged latency and acceleration
of tumorigenesis following pregnancy are two key fea-
tures of tumorigenesis in 129:Stat1−/− females. Because
the STAT1 deficiency is a germline mutation, the emer-
gence of tumors requires secondary mutations and/or
other adaptations within the microenvironment. The
prolonged latency supports the “adaptive oncogenesis”
theory, which postulates that changes in the host micro-
environment facilitate the expansion of preexisting mu-
tant populations [41]. Altered “fitness” then favors the
emergence of specific subsets of mutated cells adapted for
the new, aging environment. Although well-documented
in the hematopoietic system [42, 43], the aging micro-
environment in breast cancer has only recently been
reviewed in detail [8].
Although “aging” in mice may vary with strain, ani-
mals aged 58 weeks or older can generally be considered
“old” [44]. Mice in the present study were aged 30 to
120 weeks (2.3 years), with 38 being older than 70 weeks,
which enabled documentation of numerous age-related
pathological changes. The most dramatic nonmammary
morphological changes in the aging 129:Stat1−/− mice
occurred in the uterus and ovaries. Whereas rete cysts
of the ovary were found in aging 129:Stat1−/− animals,
they were present in both tumor-free and tumor-bearing
animals and thus cannot be considered causal. Nonethe-
less, they provide direct morphological evidence of age-
related changes in the ovary reflecting endocrine
changes in an age-related environmental milieu.
Pregnancy accelerated tumorigenesis in 129:Stat1−/−
females and reduced the median tumor onset from
91 weeks of age in nulliparous females to 78 weeks.
Studies of mouse mammary tumors in virus-induced
and GMM models have consistently shown that preg-
nancy accelerates tumorigenesis. This phenomenon has
generally been ascribed to the hormone responsiveness of
MMTV-LTR and/or other mammary-specific promoters.
Our previous mammary development experiments demon-
strated that the mammary fat pads of young 129:Stat1−/−
mice were deficient in locally derived stromal cytokines and
did not support optimal growth of the normal and neoplas-
tic mammary epithelium, but they could be reversed by ad-
ministering exogenous PRL and progesterone [2]. In the
present study, we show that transplant of primary tumors
into young nulliparous 129:Stat1−/− female hosts resulted
in much slower growth onset than in age-matched WT
hosts (Additional file 2: Figure S8).
PRL signaling appears to be a critical molecular path-
way in the etiology of impaired mammary gland devel-
opment and tumorigenesis in 129:Stat1−/− mice, in
keeping with the demonstration that heterozygous trun-
cating PRLR mutations arise in invasive tumors and
some of the MIN lesions [17]. Our finding that some of
the intraductal proliferation of the FoxA1+/ER+ LOP
cells and areas of MIN had nontruncating single-
nucleotide variants for the PRLR suggests that these
variants might be responsible for a weaker, possibly non-
progressing proliferation.
These data also highlight the potential relationship
between PRLR and ER expression in mammary cancer.
In the mammary glands of ovariectomized mice, exogen-
ous PRL suppresses estrogen- and progesterone-induced
proliferation [45], similar to findings in transgenic mice
that overexpress local PRL [46]. Estrogen and PRL
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synergistically evoke epithelial proliferation in the mam-
mary glands of pigs [47], whereas overexpression of local
PRL in the mammary glands of mice leads to ER-
positive mammary tumors [48], and PRL induces ER
expression in cultured breast cancer cells [49]. However,
cooperation between these two hormones to effect
breast cancer cell proliferation varies in accordance with
the physical properties of the cell’s microenvironment
[50], where the combination of estrogen and PRL en-
hances breast cancer cell proliferation in stiff collagen
but not in low-density collagen. Reciprocal ER and
PRLR signaling in a fibrotic microenvironment around
Stat1-null tumors may drive LOP cell proliferation.
Ductal progenitor cells, oval cells, and ducts
129:Stat1−/− mammary carcinomas are exclusively FoxA1+
as well as ER+ and PR+. Recent evidence indicates that
FoxA1, a “pioneer transcription factor” [51–53], is neces-
sary for ER expression [53–55] and for branching mor-
phogenesis in the mammary glands by maintaining ductal
and alveolar luminal cell lineages from basal stem/pro-
genitor cells [54]. ER+, PR+, and FoxA1+ MECs belong to
a class of “hormone-sensing” (HS) MECs thought to be
directly involved in mammary differentiation and in some
human breast cancers [56]. These cells stand out in
H&E-stained mammary ducts as morphologically
unique, pale, basaloid or suprabasal cells (Additional
file 2: Figure S5). They are abundant in mammary
glands from young mice but are sparse in older mice
(Additional file 2: Figure S5a–c). They resemble the
oval clear cells in the mouse mammary gland de-
scribed by Smith and Medina as “committed progeni-
tor cells” [57, 58], as well as the suprabasal clear cells
described in the human mammary gland [59–62].
FoxA1 is expressed in ductal progenitor cells [63, 64].
The location and distribution of the morphologically
unique FoxA1+ LOP cells identified in the present study
are consistent with the notion that LOP cells represent a
neoplastic form of suprabasal ductal HS-MEC progeni-
tors [56]. The presence of FoxA1+/ER+/PR+ LOP cells in
the 129:Stat1−/− mammary ducts and neoplasms is also
consistent with a ductal, rather than alveolar, origin of
the tumors (Figs. 4, 5, and 6).
The LOP cells in 129:Stat1−/− mammary glands are
larger and more pleomorphic than either the FoxA1+
cells in normal ducts or the oval clear cells described by
Smith and Medina [57, 58]. Individual LOP cells are
present in some ducts associated with MIN and their
malignant counterparts. The LOP cells also accumulate in
tumor-free mammary glands and ducts as small, atypical
lesions. As these lesions become larger, the LOP cells form
small clumps along the involved mammary duct (Fig. 3),
perhaps as abortive side branches (Figs. 4 and 6). This
phenomenon is reminiscent of the aberrant branching
morphogenesis in the developing 129:Stat1−/− mammary
gland [7], where excess abortive side buds are also present
in other GMM models [65].
The sick lobe
The human terminal duct lobular unit (TDLU) has been
identified as the most likely site of origin of most human
breast cancers [66–69]. Computer-assisted 3D recon-
structions of the mammary tree of human breasts dem-
onstrated that ductal carcinoma in situ (DCIS) is limited
to a single lobe [70, 71], with “multifocality” confined to
foci within a single “sick lobe” [72]. The “sick lobe
hypothesis” is also supported by the observation that re-
current invasive cancers and DCIS are found at the site
of the prior biopsy or excision that showed DCIS [73].
In contrast, the quiescent and nulliparous mouse mam-
mary glands do not have a specific counterpart to the
human TDLU, but they do have HS progenitor cells
immune-positive for FoxA1 that are involved in ductal
development [54]. As demonstrated here, potentially
neoplastic Stat1-null progenitor LOP cells, marked by
FoxA1, appear to be topographically limited to a single
branch of the mouse mammary tree (Fig. 5).
This “branch” (lobe)-restricted oncogenesis has not
been described in other GMM or other mouse models
of breast cancer. Carcinogenesis in most GMM models
uses alveolar MEC-specific promoters and strong onco-
genic transgenes that potentially activate oncogenic
pathways in all MECs, resulting in scattered neoplastic
foci in all branches of any given mammary gland. By
contrast, the 129:Stat1−/− mouse appears to model rela-
tively rare oncogenic events at the level of primary
branches of the mammary tree originating in the ducts
rather than the alveoli/TDLU. Thus, 129:Stat1−/−
tumorigenesis is a unique mouse model of human breast
cancers originating from ducts within an at-risk clonally
related segment/branch of the ductal tree and models
the “sick lobe” of humans.
Tumor cell factors: protumor chemotaxis
Tumor cells influence their environment by paracrine-
secreted and cell surface factors [23]. The host immune
response to the primary MIN, tumors, and transplants
was more intense and extensive than we observed in
other GMM models without specific immunostimulatory
interventions. Immune reactions to human cancers have
been broadly categorized into “immune desert” with
little or no immune cell infiltration, “inflamed” with
abundant immune cell infiltration into tumor, and “im-
mune excluded” where immune cells accumulate around
the periphery of the tumor without infiltration [39]. The
129:Stat1−/− tumors exhibit this “immune excluded”
phenotype, whereas tumors resulting from activation of
the ErbB2 or Wnt pathways have a scant host response,
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more like the “immune desert” phenotype [38, 74, 75].
In addition to connective tissue, a marked cellular re-
sponse in Stat1−/− neoplasms included macrophage and
T-cell invasion and a scattering of granulocytic cells such
as neutrophils and mast cells. Notably, macrophages have
been implicated in the fibrotic response to cancer [40].
On the basis of the observation of a high tumor “ex-
cluded infiltrate” mononuclear density [39], we postulated
that the Stat1-null tumor cells might mediate the host im-
mune response through release of cytokines and other
growth factors. Therefore, the Stat1-null tumor cell line
SSM2 was used to study macrophage migration [7]. Our
cell culture experiments suggest that Stat1-null tumor
cells secrete both macrophage migration-promoting and
macrophage migration-inhibiting factors, though we
cannot distinguish between a direct and indirect microen-
vironmental effect. Nevertheless, our data show that
chemokine secretions from Stat1−/− tumor cells have dual
effects that also help to explain the attraction but lack of
penetrance of macrophages in vivo. Macrophages are
known to have both tumor-suppressive and tumor-
promoting capacity, depending on the context. For ex-
ample, macrophages can induce fibrosis, contributing to
the stiffened tumor-promoting stroma. Soluble inhibitory
activity, meanwhile, prevents tumor-suppressive macro-
phage migration into the tumor cell interstices. This
chemokine secretion from Stat1−/− tumor cells is corrobo-
rated by the tissue localization and histopathology.
A model for tumor progression
Our observations suggest that Stat1-null LOP cells,
combined with the age-related changes in the tumor
microenvironment, contribute to the development of a
malignant neoplasm (Fig. 9). In this model, hormonal
and microenvironmental factors induce the expansion of
a FoxA1+ progenitor population. Further expansion and
transformation are the result of a rare event, often a
somatic truncating PRLR mutation, that is stochastically
favored by the increase in the susceptible progenitor
population seen with age. The increase in these progeni-
tors is also associated with aberrant side budding and
cysts originating midduct. Progression to invasive
carcinoma is preceded by a marked stromal response,
suggesting that a critical mass of intraductal cells secret-
ing chemokines is required to create a permissive/
tumor-promoting microenvironment.
Conclusions
The incidence of human breast cancer increases with
age, and luminal ER+ breast cancers are most frequent
in this population. Although luminal breast cancers typ-
ically respond to hormone therapy and carry a better
prognosis than other subtypes, this subtype accounts for
the highest mortality in all age groups. Mouse models of
this phenotype are rare, perhaps due to the difficulty in
targeting the cell of origin for these cancers. Both “basal”
and “luminal” phenotype tumors in GMM models and
Fig. 9 Schematic model of neoplastic progression in 129:Stat1−/− tumorigenesis. On the basis of data presented here, a model of neoplastic
progression can be proposed. 129:Stat1−/− renders (1) a subpopulation of Forkhead box A1-committed progenitor cells (large oval pale [LOP]
cells) susceptible to oncogenesis. On the basis of limited distribution of LOP cells within the ductal tree, this tumor progression occurs after the
beginning of ductal morphogenesis. The LOP cells have a selective advantage in the 129:Stat1−/− cytokine-poor environment. (2) With the onset
of adulthood and aging, continued proliferation of a subset of LOP cells gains further selective advantage, forming abortive (aberrant) side buds
in some contexts and (3) focal dysplastic proliferation with loss of cell polarity, identified as a mammary intraepithelial neoplasia (MIN). The earliest MIN
do not induce a significant host response, exhibit nontruncating prolactin receptor (PRLR) mutations, and generally have a morphologically identifiable
basement membrane and myoepithelial layer. (4) However, with further adaptive changes, the MIN LOP cells attract a pronounced protumor host
response of macrophages, T lymphocytes, and granulocytes, including mast cells and fibrotic extracellular matrices (microenvironmental elements). (5)
The basement membrane and myoepithelial cells become disorganized and disintegrate, with progression of MIN to invasive ductal carcinoma with
truncated PRLR mutations
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in human disease appear to arise from luminal progeni-
tors [76, 77], whereas different cells of origin give rise to
different tumor types [78]. Most GMM models with
expression of transgenes under the control of hormone-
responsive promoters such as MMTV-LTR or Wap
generally yield ER-negative tumors primarily located in
lobuloalveolar units that are presumably composed of
alveolar MECs [1, 79]. Recent work using promoters
from MEC progenitors, such as Lrg5, produce multiline-
age tumors [80]. In contrast to those studies, the
129:Stat1−/− neoplastic LOP cells express ER and FoxA1,
as well as STAT3, STAT5, PR, a truncating PRLR muta-
tion, and downstream elements such as JAK2 and
SOCS1 [16, 17]. As a result, a different type of cell, the
hormone-sensitive LOP cell, has emerged as a cell of
origin, with the resulting neoplasms originating from this
ductal progenitor cell. Segmental expansion of the FoxA1+
LOP cell population occurs with advanced age and confers
an increased risk of this ER+ phenotype cancer. In addition,
the model, in either the native 129:Stat1−/− mouse or
transplanted into WT mice, shows a consistent immune
reaction resistant to tumor immune cell infiltration, a
phenotype also common in human cancers. Thus,
129:Stat1−/− is a unique model for studying the critical
origins and risk reduction strategies in age-related ER+
breast cancer in addition to preclinical trials of hormone
and targeted therapies as well as immunotherapies.
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